Krystal Biotech
KRYS
148 hedge funds and large institutions have $1.45B invested in Krystal Biotech in 2022 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 60 increasing their positions, 41 reducing their positions, and 9 closing their positions.
133% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 9
46% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 41
8% more funds holding
Funds holding: 137 → 148 (+11)
6% more capital invested
Capital invested by funds: $1.36B → $1.45B (+$84.9M)
0.06% more ownership
Funds ownership: 81.07% → 81.12% (+0.06%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
53% less call options, than puts
Call options by funds: $5.09M | Put options by funds: $10.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
+$20M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$14.4M |
| 3 |
DM
Deerfield Management
New York
|
+$12.6M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$6.82M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$5.99M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$27.9M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$22.8M |
| 3 |
BlackRock
New York
|
-$9.83M |
| 4 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$7.45M |
| 5 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$5.56M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
151
Rockefeller Capital Management
New York
| – | -$2K | -42 | Closed |
|
|
CSS
152
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$2K | -37 | Closed |
|
|
C
153
Covestor
London,
United Kingdom
| – | -$144 | -2 | -50% |
|
|
SIC
154
SJS Investment Consulting
Sylvania,
Ohio
| – | +$72 | +1 | New |
|
|
SC
155
Schubert & Co
Mckinney,
Texas
| – | +$144 | +2 | New |
|
KRYS Hedge Fund Activity: Q3 2022 in Review
148 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Krystal Biotech (KRYS) for Q3 2022, worth a combined $1.45B — up 6.2% from $1.36B a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new KRYS positions and 9 closed out — a net gain of 12 holders — while 60 added to existing stakes and 41 trimmed.
The largest buyer was Victory Capital Management, adding an estimated $20M. The largest seller was Baker Bros. Advisors, cutting an estimated $27.9M.
- 148 institutional investors held Krystal Biotech (KRYS) as of Q3 2022, up from 137 in Q2 2022.
- Funds reported $1.45B of Krystal Biotech stock for Q3 2022, up 6.2% quarter-over-quarter.
- 21 funds opened new Krystal Biotech positions in Q3 2022 and 9 closed out, a net change of +12 holders.
- The largest Krystal Biotech buyer in Q3 2022 was Victory Capital Management, an estimated $20M added.
- The largest Krystal Biotech seller in Q3 2022 was Baker Bros. Advisors, an estimated $27.9M sold.
Based on aggregated 13F filings for Q3 2022.